LIVIVO - Search results -

Search results

Result 1 - 10 of total 141

Search options

Article ; Online: A (p)ppGpp-null mutant of Haemophilus ducreyi is partially attenuated in humans due to multiple conflicting phenotypes.

Holley, Concerta / Gangaiah, Dharanesh / Li, Wei / Fortney, Kate R / Janowicz, Diane M / Ellinger, Sheila / Zwickl, Beth / Katz, Barry P / Spinola, Stanley M

Infection and immunity

2014 Volume 82, Issue 8, Page(s) 3492–3502

Abstract: p)ppGpp responds to nutrient limitation through a global change in gene regulation patterns ... which primarily synthesize and hydrolyze (p)ppGpp in Escherichia coli. We constructed relA and relA spoT ... deletion mutants to assess the contribution of (p)ppGpp to H. ducreyi pathogenesis. Both the relA single mutant and ...

Abstract	(p)ppGpp responds to nutrient limitation through a global change in gene regulation patterns to increase survival. The stringent response has been implicated in the virulence of several pathogenic bacterial species. Haemophilus ducreyi, the causative agent of chancroid, has homologs of both relA and spoT, which primarily synthesize and hydrolyze (p)ppGpp in Escherichia coli. We constructed relA and relA spoT deletion mutants to assess the contribution of (p)ppGpp to H. ducreyi pathogenesis. Both the relA single mutant and the relA spoT double mutant failed to synthesize (p)ppGpp, suggesting that relA is the primary synthetase of (p)ppGpp in H. ducreyi. Compared to the parent strain, the double mutant was partially attenuated for pustule formation in human volunteers. The double mutant had several phenotypes that favored attenuation, including increased sensitivity to oxidative stress. The increased sensitivity to oxidative stress could be complemented in trans. However, the double mutant also exhibited phenotypes that favored virulence. When grown to the mid-log phase, the double mutant was significantly more resistant than its parent to being taken up by human macrophages and exhibited increased transcription of lspB, which is involved in resistance to phagocytosis. Additionally, compared to the parent, the double mutant also exhibited prolonged survival in the stationary phase. In E. coli, overexpression of DksA compensates for the loss of (p)ppGpp; the H. ducreyi double mutant expressed higher transcript levels of dksA than the parent strain. These data suggest that the partial attenuation of the double mutant is likely the net result of multiple conflicting phenotypes.
MeSH term(s)	Adult ; Dermatitis/microbiology ; Dermatitis/pathology ; Female ; Gene Deletion ; Genetic Complementation Test ; Guanosine Pentaphosphate/deficiency ; Haemophilus ducreyi/genetics ; Haemophilus ducreyi/pathogenicity ; Healthy Volunteers ; Humans ; Ligases/genetics ; Ligases/metabolism ; Male ; Middle Aged ; Pyrophosphatases/genetics ; Pyrophosphatases/metabolism
Chemical Substances	Guanosine Pentaphosphate (38918-96-6) ; guanosine-3',5'-bis(diphosphate) 3'-pyrophosphatase (EC 3.1.7.2) ; Pyrophosphatases (EC 3.6.1.-) ; Ligases (EC 6.-) ; guanosine 3',5'-polyphosphate synthetases (EC 6.-)
Language	English
Publishing date	2014-06-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	218698-6
ISSN	1098-5522 ; 0019-9567
ISSN (online)	1098-5522
ISSN	0019-9567
DOI	10.1128/IAI.01994-14
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 684: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Demystifying natural gas distribution grid decommissioning: An open-source approach to local deep decarbonization of urban neighborhoods

Zwickl-Bernhard, Sebastian / Auer, H.

Energy. 2022 Jan. 01, v. 238 p.121805-

2022

Abstract: In this paper, deep decarbonization in an urban neighborhood in Vienna, Austria is proposed focusing on decommissioning of the gas distribution grid for heat supply rather than trying to feed in “green” gas in the future. The core objective is to ... ...

Abstract	In this paper, deep decarbonization in an urban neighborhood in Vienna, Austria is proposed focusing on decommissioning of the gas distribution grid for heat supply rather than trying to feed in “green” gas in the future. The core objective is to demonstrate that alternative network infrastructures and energy technologies ensure not only an adequate but also an even superior provision of local heat energy services. Two different deep decarbonization pathways are studied, namely, electrification of almost all energy services and expansion of the district heating network. In addition, future district cooling service supply is considered. The method applied couples and extends two open-source models offering a complete analysis toolkit covering a high spatial and temporal resolution. The results show that deep decarbonization of local multiple-energy carrier systems is possible, without being dependent on the existing distribution grid of natural gas. Possible stranded assets (also at the gas end-user level) must not play a decisive role, especially since the trade-off analyses in this work show that alternative scenarios of lower/zero-emission energy service provision are even more economical in the longer term since the CO₂ price is expected to increase in the next decades. Future work may focus, among others, on the energy generation technology mix feeding into the district heating grid, the local mobility service needs, and a higher granularity to improve the assessment of the on-site (building-integrated) renewable generation potential associated with the emergence of energy community concepts.
Keywords	carbon dioxide ; carbon markets ; heating systems ; natural gas ; renewable energy sources ; urban areas ; zero emissions ; Austria ; Distribution grid decommissioning ; Decarbonization ; District heating/cooling ; Open-source modeling ; Urban neighborhoods
Language	English
Dates of publication	2022-0101
Publishing place	Elsevier Ltd
Document type	Article ; Online
ZDB-ID	2019804-8
ISSN	0360-5442 ; 0360-5442
ISSN (online)	0360-5442
ISSN	0360-5442
DOI	10.1016/j.energy.2021.121805
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial.

Nolan, Brendan J / Zwickl, Sav / Locke, Peter / Zajac, Jeffrey D / Cheung, Ada S

JAMA network open

2023 Volume 6, Issue 9, Page(s) e2331919

Abstract: ... a decrease in gender dysphoria (mean difference, -7.2 points; 95% CI, -8.3 to -6.1 points; P < .001 ... 6 points; 95% CI, -6.8 to -4.4 points; P < .001), and a significant decrease in suicidality (mean ... difference in SIDAS score, -6.5 points; 95% CI, -8.2 to -4.8 points; P < .001). Resolution of suicidality ...

Abstract	Importance: Testosterone treatment is a necessary component of care for some transgender and gender-diverse individuals. Observational studies have reported associations between commencement of gender-affirming hormone therapy and improvements in gender dysphoria and depression, but there is a lack of data from randomized clinical trials. Objective: To assess the effect of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in transgender and gender-diverse adults seeking masculinization. Design, setting, and participants: A 3-month open-label randomized clinical trial was conducted at endocrinology outpatient clinics and primary care clinics specializing in transgender and gender-diverse health in Melbourne, Australia, from November 1, 2021, to July 22, 2022. Participants included transgender and gender-diverse adults aged 18 to 70 years seeking initiation of testosterone therapy. Interventions: Immediate initiation of testosterone commencement (intervention group) or no treatment (standard care waiting list of 3 months before commencement). This design ensured no individuals would be waiting longer than the time to standard care. Main outcomes and measures: The primary outcome was gender dysphoria, as measured by the Gender Preoccupation and Stability Questionnaire. Secondary outcomes included the Patient Health Questionnaire-9 (PHQ-9) to assess depression and the Suicidal Ideation Attributes Scale (SIDAS) to assess suicidality. Questionnaires were undertaken at 0 and 3 months. The evaluable cohort was analyzed. Results: Sixty-four transgender and gender-diverse adults (median [IQR] age, 22.5 [20-27] years) were randomized. Compared with standard care, the intervention group had a decrease in gender dysphoria (mean difference, -7.2 points; 95% CI, -8.3 to -6.1 points; P < .001), a clinically significant decrease in depression (ie, change in score of 5 points on PHQ-9; mean difference, -5.6 points; 95% CI, -6.8 to -4.4 points; P < .001), and a significant decrease in suicidality (mean difference in SIDAS score, -6.5 points; 95% CI, -8.2 to -4.8 points; P < .001). Resolution of suicidality assessed by PHQ-9 item 9 occurred in 11 individuals (52%) with immediate testosterone commencement compared with 1 (5%) receiving standard care (P = .002). Seven individuals reported injection site pain/discomfort and 1 individual reported a transient headache 24 hours following intramuscular administration of testosterone undecanoate. No individual developed polycythemia. Conclusions and relevance: In this open-label randomized clinical trial of testosterone therapy in transgender and gender-diverse adults, immediate testosterone compared with no treatment significantly reduced gender dysphoria, depression, and suicidality in transgender and gender-diverse individuals desiring testosterone therapy. Trial registration: ANZCTR Identifier: ACTRN1262100016864.
MeSH term(s)	Adult ; Humans ; Young Adult ; Transgender Persons ; Testosterone/therapeutic use ; Testosterone Congeners ; Ambulatory Care Facilities ; Australia
Chemical Substances	Testosterone (3XMK78S47O) ; Testosterone Congeners
Language	English
Publishing date	2023-09-05
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2023.31919
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Response to Letter to the editor from Kirk & Stebbings: The Impact of Gender-Affirming Hormone Therapy on Physical Performance.

Cheung, Ada S / Zwickl, Sav / Miller, Kirsti / Nolan, Brendan J / Wong, Alex Fang Qi / Jones, Patrice / Eynon, Nir

The Journal of clinical endocrinology and metabolism

2024

Language	English
Publishing date	2024-03-19
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/clinem/dgae131
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic Krems.

Singer, Josef / Brauneck, Elias / Zwickl-Traxler, Elisabeth / Pecherstorfer, Martin

Translational oncology

2021 Volume 14, Issue 5, Page(s) 101021

Abstract: ... treated patients (p = 0,0165 with a median PFS of 151 days, compared to 83 days in the chemotherapy group ...

Abstract	Background and aim: To successfully apply personalized cancer therapies, thorough understanding of the patient's tumor is needed. In-depth, comprehensive genomic profiling systems allow gathering this knowledge by testing hundreds of cancer-related genes. Several large institutions have established precision oncology programs in recent years with promising results for patients. However, especially middle-sized oncologic institutions face challenges to implement such programs. This study aims to retrospectively analyze the effects of comprehensive genomic tumor profiling with respect to feasibility and effectiveness in a middle-sized oncologic center in Austria. Methods: From May 1st, 2016 to December 31st, 2019 patients at the University Clinic Krems, who suffered from CUP-syndromes plus patients, who were resistant to conventional therapy or have progressed after all available therapy lines, were offered to get their tumors analyzed by comprehensive genomic profiling in order to establish a customized therapy. Results: Of 69 considered patients, 64 patients' samples could be profiled. The median number of detected alterations was 4 (minimum 0; maximum 23). Most frequent alterations were reported for TP53, KRAS and CDKN2A/B. In 13 patients (20% of 64 successful profiles), personalized therapies could be initiated. 22 patients were treated with another line of chemotherapy as no actionable alteration could be detected. Effectiveness, determined by a PFS of the newly initiated therapy longer than 130% of the last conventional therapy line, could be seen in 8 of 13 patients (61,5%) of the precision oncology cohort compared to only 3 of 22 patients (13,5%) in the chemotherapy group. Additionally, Kaplan-Meier curves of PFS demonstrate a significant benefit for personalized treated patients (p = 0,0165 with a median PFS of 151 days, compared to 83 days in the chemotherapy group). Conclusion: In summary, personalized cancer therapy based on comprehensive genomic profiling is effective and feasible also in the setting of a middle-sized oncologic center.
Language	English
Publishing date	2021-02-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233
ISSN	1936-5233
DOI	10.1016/j.tranon.2021.101021
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Impact of Gender-Affirming Hormone Therapy on Physical Performance.

Cheung, Ada S / Zwickl, Sav / Miller, Kirsti / Nolan, Brendan J / Wong, Alex Fang Qi / Jones, Patrice / Eynon, Nir

The Journal of clinical endocrinology and metabolism

2023 Volume 109, Issue 2, Page(s) e455–e465

Abstract: Context: The inclusion of transgender people in elite sport has been a topic of debate. This narrative review examines the impact of gender-affirming hormone therapy (GAHT) on physical performance, muscle strength, and markers of endurance.: Evidence ... ...

Abstract	Context: The inclusion of transgender people in elite sport has been a topic of debate. This narrative review examines the impact of gender-affirming hormone therapy (GAHT) on physical performance, muscle strength, and markers of endurance. Evidence acquisition: MEDLINE and Embase were searched using terms to define the population (transgender), intervention (GAHT), and physical performance outcomes. Evidence synthesis: Existing literature comprises cross-sectional or small uncontrolled longitudinal studies of short duration. In nonathletic trans men starting testosterone therapy, within 1 year, muscle mass and strength increased and, by 3 years, physical performance (push-ups, sit-ups, run time) improved to the level of cisgender men. In nonathletic trans women, feminizing hormone therapy increased fat mass by approximately 30% and decreased muscle mass by approximately 5% after 12 months, and steadily declined beyond 3 years. While absolute lean mass remains higher in trans women, relative percentage lean mass and fat mass (and muscle strength corrected for lean mass), hemoglobin, and VO2 peak corrected for weight was no different to cisgender women. After 2 years of GAHT, no advantage was observed for physical performance measured by running time or in trans women. By 4 years, there was no advantage in sit-ups. While push-up performance declined in trans women, a statistical advantage remained relative to cisgender women. Conclusion: Limited evidence suggests that physical performance of nonathletic trans people who have undergone GAHT for at least 2 years approaches that of cisgender controls. Further controlled longitudinal research is needed in trans athletes and nonathletes.
MeSH term(s)	Male ; Humans ; Female ; Cross-Sectional Studies ; Transsexualism/drug therapy ; Testosterone/therapeutic use ; Transgender Persons ; Physical Functional Performance
Chemical Substances	Testosterone (3XMK78S47O)
Language	English
Publishing date	2023-07-11
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/clinem/dgad414
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Epidemiology of Intensive Care Patients Classified as a Third Sex in Australia and New Zealand.

Modra, Lucy J / Higgins, Alisa M / Pilcher, David V / Cheung, Ada S / Carpenter, Morgan N / Bailey, Michael / Zwickl, Sav / Bellomo, Rinaldo

Chest

2023

Abstract: ... 18.4 years; P = .02) or male (63.2 ± 16.7 years; P < .001), respectively. Patients classified ...

Abstract	Background: Patient sex affects treatment and outcomes in critical illness. Previous studies of sex differences in critical illness compared female and male patients. In this study, we describe the group of patients classified as a third sex admitted to ICUs in Australia and New Zealand. Research question: What are the admission characteristics and outcomes of ICU patients classified as belonging to a third sex group compared with patients classified as female or male? Study design and methods: Retrospective observational study of admissions to 200 ICUs, recorded in the Australian and New Zealand Intensive Care Society's Adult Patient Database from 2018 to 2022. We undertook mixed effect logistic regression to compare hospital mortality across the sex groups, adjusted for illness severity, diagnosis, treatment limitation, year, and hospital. Results: We examined 892,161 admissions, of whom 525 (0.06%) were classified as third sex. Patients classified as third sex were represented across all diagnostic categories, jurisdictions, and hospital types. On average, they were younger than the groups classified as female (59.2 ± 20.0 vs 61.3 ± 18.4 years; P = .02) or male (63.2 ± 16.7 years; P < .001), respectively. Patients classified as third sex were more likely to be admitted after orthopedic surgery (10.1% third sex admissions [95% CI, 7.7%-13.0%]; 6.2% female [95% CI, 6.1%-6.3%]; 4.8% male [95% CI, 4.7%-4.9%]) and drug overdose (8.8% third sex admissions [95% CI, 6.5%-11.5%]; 4.2% female [95% CI, 4.1%-4.2%]; 3.1% male [95% CI, 3.0%-3.1%]). There was no difference in the adjusted hospital mortality of patients classified as third sex compared with the other groups. Interpretation: Patients classified as third sex composed a small minority group of adult ICU patients. This group had a different diagnostic case mix but similar outcomes to the groups classified as female or male. Further characterizing a third sex group will require improved processes for recording sex and gender in health records.
Language	English
Publishing date	2023-12-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	1032552-9
ISSN	1931-3543 ; 0012-3692
ISSN (online)	1931-3543
ISSN	0012-3692
DOI	10.1016/j.chest.2023.11.043
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui III Zs.45: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 349: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals.

Nolan, Brendan J / Zwickl, Sav / Locke, Peter / Simpson, Satu / Li, Ling / Zajac, Jeffrey D / Cheung, Ada S

The journal of sexual medicine

2022 Volume 19, Issue 6, Page(s) 1049–1054

Abstract: ... masculinization. Nolan BJ, Zwickl S, Locke P, et al. Prescription Patterns and Testosterone Concentrations ...

Abstract	Background: Masculinizing hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity in trans and gender diverse individuals. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered. 100 mg AndroForte 5% testosterone cream is the recommended starting dose in hypogonadal cisgender men but there are no data evaluating the use of AndroForte 5% testosterone cream in gender-affirming hormone therapy regimens. Aim: To assess the prescription patterns and serum total testosterone concentrations achieved with AndroForte 5% testosterone cream in trans and gender diverse individuals. Methods: A retrospective analysis was undertaken of trans and gender diverse individuals at a primary and secondary care clinic in Melbourne, Australia. Seventy-two individuals treated with AndroForte 5% testosterone cream to the torso were included. Outcomes: Testosterone dose and serum total testosterone concentration. Results: Median age was 26 years (IQR 22-30) and median duration of testosterone therapy was 14 months (7-24). Fifty (69%) individuals had a non-binary gender identity. Initial median testosterone dose was 50 mg (50-100) daily. Thirty-eight (53%) commenced doses <100 mg daily, the recommended starting dose for hypogonadal cisgender men. Median total testosterone concentration achieved from 186 individual laboratory results was 11.9 nmol/L (8.1-16.4). Polycythemia was documented in 5 (7%) individuals. Clinical implications: AndroForte 5% testosterone cream can be used in individuals with a binary and/or non-binary gender identity seeking masculinization. It can be commenced at a lower dose than that administered to hypogonadal cisgender men for individuals seeking slow masculinization goals. Strengths & limitations: Limitations include the retrospective study design, lack of clinical end points and lack of standardization of timing of laboratory tests in relation to the last dose. This is the first study to evaluate AndroForte 5% testosterone cream in trans and gender diverse individuals and provides insights into prescription patterns in individuals with a non-binary gender identity. Conclusion: AndroForte 5% testosterone cream represents an alternative formulation of testosterone administration for trans and gender diverse individuals seeking masculinization. Nolan BJ, Zwickl S, Locke P, et al. Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals. J Sex Med 2022;19:1049-1054.
MeSH term(s)	Adult ; Female ; Gender Identity ; Humans ; Male ; Prescriptions ; Retrospective Studies ; Testosterone/therapeutic use ; Transgender Persons
Chemical Substances	Testosterone (3XMK78S47O)
Language	English
Publishing date	2022-03-30
Publishing country	Netherlands
Document type	Case Reports ; Research Support, Non-U.S. Gov't
ZDB-ID	2251959-2
ISSN	1743-6109 ; 1743-6095
ISSN (online)	1743-6109
ISSN	1743-6095
DOI	10.1016/j.jsxm.2022.02.020
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6417: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 505: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prospective study to compare axial position stability after fellow-eye implantation of 2 distinct intraocular lens designs.

Hienert, Julius / Hirnschall, Nino / Ruiss, Manuel / Ullrich, Marlies / Zwickl, Hannah / Findl, Oliver

Journal of cataract and refractive surgery

2021 Volume 47, Issue 8, Page(s) 999–1005

Abstract: ... significantly different in eyes implanted with the C-loop IOL compared with the 4-point haptic IOL (P < .001 ... The overall IOL shift was 0.25 ± 0.16 mm for the 4-point haptic IOL and 0.14 ± 0.09 mm for the C-loop IOL (P ...

Abstract	Purpose: To compare the dynamics of axial intraocular lens (IOL) position and stability in the capsular bag after fellow-eye implantation of a 1-piece C-loop and a 4-point haptic IOL. Setting: Hanusch Hospital, Vienna. Design: Prospective, comparative, randomized bilateral study. Methods: One hundred eyes of 50 patients were randomly implanted with a C-loop IOL (CT LUCIA 611P) in 1 eye and a 4-point haptic IOL (CT ASPHINA 409MP) in the other eye. Anterior chamber depth (ACD) was measured at 1 week (W1), 1 month (M1), and 4 to 6 months (M4-6) postoperatively using a swept-source optical coherence tomography device (IOLMaster 700). Uncorrected distance visual acuity (UDVA), corrected distance visual acuity, and subjective refraction outcomes were assessed at M4-6 postoperative follow-up. Results: Hundred eyes of 50 patient were included. Pseudophakia ACD values at W1, M1, and M4-6 timepoints were significantly different in eyes implanted with the C-loop IOL compared with the 4-point haptic IOL (P < .001). The overall IOL shift was 0.25 ± 0.16 mm for the 4-point haptic IOL and 0.14 ± 0.09 mm for the C-loop IOL (P < .001). The M4-6 mean monocular UDVA outcome for eyes with C-loop IOL was 0.06 ± 0.14 logarithm of the minimum angle of resolution (logMAR) and 0.03 ± 0.10 logMAR for the eyes with 4-point haptic IOL. M4-6 mean spherical equivalent was -0.32 ± 0.48 diopter (D) in the C-loop IOL group and -0.33 ± 0.42 D in the 4-point haptic IOL group. Conclusions: Statistically significant differences in IOL design results in different postoperative ACD values. No relevant or statistically significant differences were found in refraction or visual acuity between the groups.
Language	English
Publishing date	2021-02-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	632744-8
ISSN	1873-4502 ; 0886-3350
ISSN (online)	1873-4502
ISSN	0886-3350
DOI	10.1097/j.jcrs.0000000000000557
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1806: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals.

Nolan, Brendan J / Zwickl, Sav / Wong, Alex F Q / Locke, Peter / Simpson, Satu / Li, Ling / Zajac, Jeffrey D / Cheung, Ada S

Therapeutic advances in endocrinology and metabolism

2022 Volume 13, Page(s) 20420188221083512

Abstract: Background: Masculinising hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically ... ...

Abstract	Background: Masculinising hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered, although there are currently limited data evaluating the use of 1% testosterone gel in gender-affirming hormone therapy regimens. Objectives: The objective of the study was to assess the prescription patterns and serum total testosterone concentrations achieved with 1% testosterone gel in trans and gender diverse individuals. Materials and methods: A retrospective cross-sectional analysis was undertaken of trans individuals at a primary and secondary care clinic in Melbourne, Australia. Sixty-seven individuals treated with 1% testosterone gel were included. Primary outcomes were testosterone dose and serum total testosterone concentration achieved. Results: Median age was 25 (22-30) years and median duration of testosterone therapy was 12 (7-40) months. Thirty-five (52%) individuals had a nonbinary gender identity. Initial median testosterone dose was 25 mg (12.5-31.3) daily. Fifty-two (78%) individuals commenced doses <50 mg daily, the recommended starting dose for hypogonadal cisgender men. Median total testosterone concentration achieved was 11.9 nmol/l (7.3-18.6). Polycythaemia (haematocrit >0.5) was documented in eight of 138 (6%) laboratory results in six individuals. Discussion and conclusions: One percent testosterone gel achieves serum total testosterone concentrations in the cisgender male reference range. A high proportion of individuals had a nonbinary gender identity and most individuals commenced a lower dose than that typically administered to hypogonadal cisgender men, potentially related to slow or 'partial' masculinisation goals.
Language	English
Publishing date	2022-03-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	2554822-0
ISSN	2042-0196 ; 2042-0188
ISSN (online)	2042-0196
ISSN	2042-0188
DOI	10.1177/20420188221083512
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito